Sign in
Taking people in United StatesPhase 2

Tests quisinostat to prevent uveal melanoma from spreading

Tests quisinostat in adults with high-risk uveal melanoma after initial treatment.

Key facts

Who runs it
University of Miami
Where
Miami, United StatesSee the site
Trial code
Registry title
Adjuvant Quisinostat in High-Risk Uveal Melanoma
Status
Recruiting
Phase
Phase 2
People taking part
63 people, planned
Started
27 May 2025
Expected to end
27 May 2030
Type of study
Interventional
Treatments tested
  • Quisinostat
Record updated
18 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a newly diagnosed, high-risk uveal melanoma (an eye cancer) that has not spread. It tests quisinostat after the main treatment.

Age
Older than 18 years.
Sex
All sexes can join.
Disease stage
Primary uveal melanoma, at least 12 mm across at its widest point. High-risk (class 2) by a gene test. No sign of spread to other parts of the body.
Earlier treatment
The main treatment of the eye tumor must have finished within 183 days before the trial drug starts. People cannot join if they had other treatment after it, or ever took an HDAC inhibitor.
Biomarker or test result
High-risk (class 2) by gene expression profiling (DecisionDx-UM).

Main reasons for not taking part

  • Another cancer that is getting worse or needs active treatment
  • Known HIV infection on antiretroviral therapy, or active hepatitis B or C
  • Heart rhythm problems, a QTcB of 480 msec or more, or long QT syndrome
  • Uncontrolled illness, such as an active infection or symptomatic heart failure
  • Other study drugs taken within 28 days or five half-lives, whichever is shorter

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Primary diagnosis of uveal melanoma (UM) with a lesion of at least 12 mm in largest basal diameter (LBD) as clinically determined by the treating Investigator. Cytologic determination of diagnosis is not required. Size is based on clinical assessment (e.g., by ultrasound or direct ophthalmoscopy) prior to enucleation or radiation therapy
  • Definitive therapy of the primary UM must have been completed within 183 days of initiating protocol therapy
  • High-risk (class 2) UM as determined by gene expression profiling (GEP; DecisionDx-UM, Castle Biosciences Inc., Friendswood, TX)
  • No evidence of metastatic disease
  • Patients aged >18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Life expectancy of greater than 3 months
  • Ability to swallow and retain orally administered medication and no clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels
  • Adequate organ and marrow function as defined by the local institutional lab and treating physician
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 6 months after completion of quisinostat administration. Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to study entry
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Additional malignancy that is progressing or requires active treatment. Exceptions include the following cancers: basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer, ductal carcinoma in situ (DCIS), incidentally discovered asymptomatic thyroid cancer, elevated levels of prostate-specific antigen (PSA) stable on hormonal therapy with no otherwise detectable disease, and a previous diagnosis of malignancy that has shown no evidence of disease progression for 2 years or longer
  • Any major surgery or extensive radiotherapy except that which is required for definitive treatment of primary UM
  • Previous adjuvant treatment for UM after definitive primary tumor therapy
  • History of prior Histone Deacetylase (HDAC) inhibitor use
  • Patients that cannot be taken off medications that are potent inhibitors of cytochrome (CYP) 3a4/A5 (CYP3a4/A5) and CYP2C9. Inclusion of these patients and of patients on warfarin will require discussion and approval by the Sponsor-Investigator prior to enrollment
  • Use of other investigational drugs within 28 days or five half-lives, whichever is shorter, with a minimum of 14 days from the last dose preceding the first dose of study treatment and during the study
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to quisinostat
  • Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection except for patients with cleared HBV and HCV infection demonstrated by undetectable viral levels by polymerase chain reaction (PCR). HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with quisinostat
  • Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, New York Heart Association (NYHA) Classifications 2-4, or psychiatric illness/social situations that would limit compliance with study requirements
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • A QT interval corrected for heart rate using the Bazett's formula (QTcB) ≥ 480 msec or history of long QT syndrome
  • Patients with a cardiac ejection fraction outside of the normal range as defined by institutional standards or with a history of clinically significant cardiac arrhythmia as determined by a cardiologist
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or that makes participation in the trial to be not in the best interest of the patient in the opinion of the treating Investigator
  • Impaired decision-making capacity

Where in United States

  • University of MiamiMiami, United StatesContact: Christine EstevezTaking people

About the trial

What the trial wants to find out

The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.

The group in the trial

  • Quisinostat Treatment GroupTreatment being tested

    Participants will receive up to Quisinostat treatment for up to 17 cycles, each cycle lasting 21 days, for a total treatment period of up to 51 weeks. Participants will be followed for up to 2 years after end of treatment until disease progression. Total participation duration is about three years.

    Treatment: Quisinostat

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Trial of Adjuvant Quisinostat in High-Risk Uveal Melanoma
Plain-language title
Tests quisinostat to prevent uveal melanoma from spreadingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 June 2026